PL3206692T3 - Leczenie choroby stłuszczeniowej wątroby z zastosowaniem antagonistów receptorów glukokortykoidowych i mineralokortykoidowych - Google Patents

Leczenie choroby stłuszczeniowej wątroby z zastosowaniem antagonistów receptorów glukokortykoidowych i mineralokortykoidowych

Info

Publication number
PL3206692T3
PL3206692T3 PL15851238.4T PL15851238T PL3206692T3 PL 3206692 T3 PL3206692 T3 PL 3206692T3 PL 15851238 T PL15851238 T PL 15851238T PL 3206692 T3 PL3206692 T3 PL 3206692T3
Authority
PL
Poland
Prior art keywords
glucocorticoid
receptor antagonists
liver disease
fatty liver
disease treatment
Prior art date
Application number
PL15851238.4T
Other languages
English (en)
Polish (pl)
Inventor
Joseph K. Belanoff
Hazel Hunt
Onno C. MEIJER
Jose VAN DEN HEUVEL
Original Assignee
Corcept Therapeutics Incorporated
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Corcept Therapeutics Incorporated filed Critical Corcept Therapeutics Incorporated
Publication of PL3206692T3 publication Critical patent/PL3206692T3/pl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PL15851238.4T 2014-10-15 2015-10-14 Leczenie choroby stłuszczeniowej wątroby z zastosowaniem antagonistów receptorów glukokortykoidowych i mineralokortykoidowych PL3206692T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462064358P 2014-10-15 2014-10-15
US201462092041P 2014-12-15 2014-12-15
PCT/US2015/055487 WO2016061195A1 (en) 2014-10-15 2015-10-14 Fatty liver disease treatment using glucocorticoid and mineralocorticoid receptor antagonists

Publications (1)

Publication Number Publication Date
PL3206692T3 true PL3206692T3 (pl) 2024-07-22

Family

ID=55747256

Family Applications (1)

Application Number Title Priority Date Filing Date
PL15851238.4T PL3206692T3 (pl) 2014-10-15 2015-10-14 Leczenie choroby stłuszczeniowej wątroby z zastosowaniem antagonistów receptorów glukokortykoidowych i mineralokortykoidowych

Country Status (22)

Country Link
US (5) US10238659B2 (OSRAM)
EP (2) EP4353310A3 (OSRAM)
JP (1) JP6761410B2 (OSRAM)
KR (1) KR102435956B1 (OSRAM)
CN (2) CN111557942B (OSRAM)
AU (1) AU2015333645B2 (OSRAM)
BR (1) BR112017007860B1 (OSRAM)
CA (1) CA2964625C (OSRAM)
DK (1) DK3206692T3 (OSRAM)
ES (1) ES2978871T3 (OSRAM)
FI (1) FI3206692T3 (OSRAM)
IL (1) IL251729B (OSRAM)
MX (1) MX2017004943A (OSRAM)
NZ (1) NZ731060A (OSRAM)
PH (1) PH12017500710B1 (OSRAM)
PL (1) PL3206692T3 (OSRAM)
PT (1) PT3206692T (OSRAM)
RU (1) RU2718921C2 (OSRAM)
SG (1) SG11201703024VA (OSRAM)
UA (1) UA123537C2 (OSRAM)
WO (1) WO2016061195A1 (OSRAM)
ZA (1) ZA201702813B (OSRAM)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PH12017500710B1 (en) 2014-10-15 2024-01-17 Corcept Therapeutics Inc Fatty liver disease treatment using glucocorticoid and mineralocorticoid receptor antagonists
SG11202011948SA (en) * 2018-06-04 2020-12-30 Corcept Therapeutics Inc Pyrimidine cyclohexenyl glucocorticoid receptor modulators
AU2020239920A1 (en) 2019-03-18 2021-11-04 Arnold L. Newman Method of improving insulin sensitivity
US11548856B2 (en) * 2020-05-06 2023-01-10 Corcept Therapeutics Incorporated Polymorphs of pyrimidine cyclohexyl glucocorticoid receptor modulators
US12144812B2 (en) * 2020-05-06 2024-11-19 Corcept Therapeutics Incorporated Formulations of pyrimidine cyclohexyl glucocorticoid receptor modulators
KR102481705B1 (ko) * 2020-08-04 2022-12-27 연세대학교 산학협력단 트리아졸 유도체를 유효성분으로 포함하는 간 섬유증의 예방 또는 치료용 조성물
WO2022140293A1 (en) * 2020-12-21 2022-06-30 Corcept Therapeutics Incorporated Method of preparing pyrimidine cyclohexyl glucocorticoid receptor modulators
WO2022235647A1 (en) * 2021-05-05 2022-11-10 Corcept Therapeutics Incorporated Methods for reducing liver fat and for treating fatty liver disorders
WO2025174745A1 (en) * 2024-02-12 2025-08-21 Corcept Therapeutics Incorporated MIRICORILANT TREATMENT FOR FATTY LIVER DISEASES and its EFFECTS on LIVER FAT CONTENT, FATTY ACIDS, ACYLGLYCEROLS, and SECONDARY BILE ACIDS
WO2025255357A1 (en) * 2024-06-06 2025-12-11 Corcept Therapeutics Incorporated Methods for preparing and maintaining livers and portions thereof for liver transplantation

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2153546A (en) 1936-07-29 1939-04-11 Universal Draft Gear Attachmen Hand brake actuating mechanism
US4391904A (en) 1979-12-26 1983-07-05 Syva Company Test strip kits in immunoassays and compositions therein
GB0213745D0 (en) * 2002-06-14 2002-07-24 Univ Edinburgh Enzyme
AU2003251970A1 (en) 2002-07-18 2004-02-09 Bristol-Myers Squibb Company Modulators of the glucocorticoid receptor and method
ATE463479T1 (de) 2005-05-18 2010-04-15 Merck Sharp & Dohme D-homoandrosta-17-yl-carbamat-derivate als selektive glucocorticoid-rezeptor-liganden
US8389472B2 (en) * 2005-08-19 2013-03-05 Amylin Pharmaceuticals, Llc Exendin-4 to treat nonalcoholic steatohepatitis and nonalcoholic fatty liver disease
WO2007035759A1 (en) * 2005-09-19 2007-03-29 Johnson & Johnson Pharmaceutical Research & Development L.L.C. Modulation of glucocorticoid receptor expression
GB0601092D0 (en) * 2006-01-19 2006-03-01 Daniolabs Ltd The Prevention Of Systemic Side-Effects Of Glucocorticoids
HUE026057T2 (en) 2006-05-09 2016-05-30 Genzyme Corp Procedures for the Treatment of Fatty Liver Disease, which comprises inhibition of glycosphingolipid synthesis
US9623021B2 (en) 2007-01-22 2017-04-18 Gtx, Inc. Nuclear receptor binding agents
PE20090695A1 (es) 2007-04-13 2009-06-27 Schering Corp Derivados de pirimidindiona como agonistas del receptor de acido nicotinico
WO2009155481A1 (en) 2008-06-20 2009-12-23 Gtx, Inc. Metabolites of selective androgen receptor modulators and methods of use thereof
EA022924B1 (ru) 2009-04-03 2016-03-31 Ф.Хоффманн-Ля Рош Аг ТВЁРДАЯ ФОРМА {3-[5-(4-ХЛОРФЕНИЛ)-1Н-ПИРРОЛО[2,3-b]ПИРИДИН-3-КАРБОНИЛ]-2,4-ДИФТОРФЕНИЛ}АМИДА ПРОПАН-1-СУЛЬФОНОВОЙ КИСЛОТЫ И ЕЁ ПРИМЕНЕНИЕ
CN103596431B (zh) 2011-03-18 2016-06-22 科赛普特治疗公司 嘧啶环己基糖皮质激素受体调节剂
PH12017500710B1 (en) 2014-10-15 2024-01-17 Corcept Therapeutics Inc Fatty liver disease treatment using glucocorticoid and mineralocorticoid receptor antagonists

Also Published As

Publication number Publication date
US12226417B2 (en) 2025-02-18
AU2015333645B2 (en) 2020-01-30
AU2015333645A1 (en) 2017-05-04
BR112017007860A2 (pt) 2018-01-16
US20210085682A1 (en) 2021-03-25
EP3206692A4 (en) 2018-05-30
US20160106749A1 (en) 2016-04-21
FI3206692T3 (fi) 2024-05-06
NZ731060A (en) 2023-07-28
CA2964625C (en) 2023-03-07
PT3206692T (pt) 2024-04-30
CN107106562A (zh) 2017-08-29
JP2017531013A (ja) 2017-10-19
CN111557942A (zh) 2020-08-21
RU2017114596A (ru) 2018-11-15
US10881660B2 (en) 2021-01-05
US20250221995A1 (en) 2025-07-10
CN111557942B (zh) 2023-10-03
SG11201703024VA (en) 2017-05-30
EP3206692A1 (en) 2017-08-23
EP4353310A2 (en) 2024-04-17
EP3206692B1 (en) 2024-04-03
JP6761410B2 (ja) 2020-09-23
DK3206692T3 (da) 2024-04-29
US11590135B2 (en) 2023-02-28
PH12017500710B1 (en) 2024-01-17
MX2017004943A (es) 2017-07-19
CN107106562B (zh) 2020-08-18
PH12017500710A1 (en) 2017-10-09
KR20170066646A (ko) 2017-06-14
ZA201702813B (en) 2019-05-29
RU2017114596A3 (OSRAM) 2019-05-08
UA123537C2 (uk) 2021-04-21
US20230218621A1 (en) 2023-07-13
CA2964625A1 (en) 2016-04-21
RU2718921C2 (ru) 2020-04-15
IL251729B (en) 2020-03-31
US10238659B2 (en) 2019-03-26
US20190151318A1 (en) 2019-05-23
ES2978871T3 (es) 2024-09-23
IL251729A0 (en) 2017-06-29
EP4353310A3 (en) 2024-06-19
WO2016061195A1 (en) 2016-04-21
BR112017007860B1 (pt) 2023-03-07
KR102435956B1 (ko) 2022-08-23

Similar Documents

Publication Publication Date Title
ZA201702813B (en) Fatty liver disease treatment using glucocorticoid and mineralocorticoid receptor antagonists
IL247713A0 (en) Indazole 3-carboxyamides converted at the 5-position, their preparation and their use
SG11201609645YA (en) Device for connecting the structural elements of ribs and reticular structures
AU201710083S (en) Bowl and Covered Bowl
GB201404470D0 (en) Therapeutic methods and materials
AU357565S (en) Mixing bowls
IL246779A0 (en) Methods for the treatment and prevention of kidney disorders and fatty liver disorders
ZA201706671B (en) Process for the preparation of androgen receptor antagonists and intermediates thereof
SG11201608217PA (en) Fatty acid composition and use thereof
IL246489A0 (en) Methods for using anti-steap1 antibodies and immunoconjugates
IL249203A0 (en) Androgen receptor modulators and methods of using them
GB2530559B (en) Mixing bowl
IL265560A (en) Preparations containing a mineralocorticoid receptor antagonist and their uses
PT3113774T (pt) Composições de grapiprant e métodos de utilização das mesmas
IL247828A0 (en) Progesterone compounds
IL246944B (en) A process for the preparation of abiraterone acetate and its intermediates
GB201612052D0 (en) Animal claw shearing apparatuses and methods of using the same
GB201810451D0 (en) Anti-placenta-chondroitin-sulfate chimeric antigen receptor and application thereof
GB201520661D0 (en) Mixing bowl
GB201411741D0 (en) Mixing bowl stand
GB201402210D0 (en) Mixing bowl
GB201419977D0 (en) Dynamic mixer and mixing
GB201402629D0 (en) Improved mixer and associated methods
GB201419559D0 (en) Therapeutic compositions and methods